author-photo

Angelika Freitag

German Cancer Research Center

6

Papers

39

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

2020 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (12)
The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
INFORM2 exploratory multinational phase I/II combination study of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies: INFORM2 NivEnt.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.

2019 Clinical Epigenetics
Show All
- Source
- Cite
- Save
Citations (6)
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial

2018 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (3)